Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | CEL | P19835 | 2/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | PTPN5 | P54829 | 2/20 | 0.36 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.36 |
| ▸ | NAAA | Q02083 | 1/20 | 0.36 |
| ▸ | KMO | O15229 | 1/20 | 0.36 |
| ▸ | PTPRC | P08575 | 1/20 | 0.36 |
| ▸ | PTPRF | P10586 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | CDC25B | P30305 | 1/20 | 0.36 |
| ▸ | TDO2 | P48775 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2045879 | 0.90 | RBP4 (0.37) | PTGDR2MEN1KMT2A | |
| SCHEMBL4871817 | 0.81 | HTR2C (0.55) | — | |
| SCHEMBL251063 | 0.80 | ADRA1A (0.45) | PTGDR2PTGS2KMT2A | |
| SCHEMBL22288194 | 0.80 | PTGDR2 (0.42) | PTGDR2PTGS2MEN1KMT2AHSP90AA1 | |
| Hydrogen Peroxide SCHEMBL3679819 | 0.78 | PTGDR2 (0.55) | PTGDR2PTGS2MEN1KMT2ACEL | |
| Hydrogen Peroxide SCHEMBL11398422 | 0.78 | PTGDR2 (0.55) | PTGDR2PTGS2MEN1KMT2ACEL | |
| SCHEMBL42781 | 0.78 | PTGDR2 (0.48) | PTGDR2PTGS2CELPTPRCPTPRF | |
| SCHEMBL2019967 | 0.78 | ADRA1A (0.46) | PTGDR2KMT2A | |
| SCHEMBL28910683 | 0.78 | PTGDR2 (0.40) | PTGDR2PTGS2MEN1KMT2ABCHE | |
| SCHEMBL1813761 | 0.77 | PTGDR2 (0.44) | PTGDR2PTGS2MEN1KMT2APTPN5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6476266-B1 | Diamino compound and production process for the same | CHISSO CORPORATION (JP) | 2002-11-05 | — | — | US | claimed |
| EP-0417721-A2 | Novel peptidase and isomerase inhibitors | MERRELL DOW PHARMACEUTICALS INC. (US) | 1991-03-20 | — | — | EP | claimed |
| EP-1948211-A2 | MODULATORS OF NOD1 SIGNALING | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2008-07-30 | — | — | EP | disclosed |
| WO-2007044989-A2 | MODULATORS OF NOD1 SIGNALING | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2007-04-19 | — | — | WO | disclosed |
| US-6562849-B1 | Amine compound or pharmacologically acceptable salt thereof. These compounds are useful in the treatment and/or prophylaxis of diseases such as diabetes, hyperlipemia, arteriosclerosis, cancer, etc. | SANKYO COMPANY, LIMITED (JP) | 2003-05-13 | — | — | US | disclosed |
| US-20030078426-A1 | Amine derivative compounds | SANKYO COMPANY, LIMITED (JP) | 2003-04-24 | — | — | US | disclosed |
| US-6476266-B1 | Diamino compound and production process for the same | CHISSO CORPORATION (JP) | 2002-11-05 | — | — | US | disclosed |
| US-6476266-B1 | Diamino compound and production process for the same | CHISSO CORPORATION (JP) | 2002-11-05 | — | — | US | disclosed |
| EP-1167366-A1 | AMINE DERIVATIVES | Sankyo Company, Limited (JP) | 2002-01-02 | — | — | EP | disclosed |
| JP-2000191605-A | DIAMINO COMPOUND AND ITS PRODUCTION | CHISSO CORP | 2000-07-11 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078426-A1 | Amine derivative compounds | H1-10, APOB, PRMT1 | PTGDR2 3866/4885PTGS2 3736/4885MEN1 300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.